RP1 Combination Wins Accelerated Melanoma Approval

DecisionWhat the FDA authorized

On August 6, 2026 in the United States, the FDA granted accelerated approval to vusolimogene oderparepvec-wtpg, marketed as Tudriqev and developed as RP1, in combination with nivolumab. The date was August 7 in Beijing.

The indication is limited to adults with unresectable or metastatic cutaneous melanoma whose disease progressed on a prior anti-PD-1-based regimen. It is an approval of the combination in this post-PD-1 setting, not RP1 monotherapy and not a first-line authorization for melanoma generally.

MechanismA local injection paired with systemic immunotherapy

RP1 is an oncolytic immunotherapy administered by injection into tumors. It is designed to disrupt infected tumor cells and increase immune recognition of tumor material. Nivolumab blocks PD-1, removing one brake on T-cell activity.

The proposed logic is complementary: use the injected tumor as a site of immune activation while nivolumab supports a broader systemic response. Responses observed in non-injected lesions are consistent with that hypothesis, but biological consistency is not a substitute for controlled evidence of clinical benefit.

EvidenceWhat the IGNYTE study showed

The registrational evidence came from the phase 1/2 IGNYTE study. Its relevant cohort included 140 patients with advanced melanoma and confirmed progression on an anti-PD-1-based regimen who received intratumoral RP1 with intravenous nivolumab.

An objective response rate near one-third means that predefined tumor shrinkage was confirmed in roughly one of every three study participants. Duration of response asks a different question: among responders, how long did the response persist? Both were central to the accelerated approval decision.

A durable response signal can support accelerated approval; it does not by itself prove that a treatment extends survival compared with another therapy.

LimitsWhat the study cannot establish

IGNYTE was a single-arm study. Without a randomized comparator, it cannot directly measure the combination's advantage over another treatment, establish a causal overall-survival benefit, or fully isolate RP1's contribution from nivolumab.

• Response rate is a tumor-measurement endpoint, not the same as living longer or feeling better.
• Cross-study comparisons can mislead because eligibility, disease burden, prior treatment and follow-up differ.
• Results from a selected trial population may not reproduce exactly in broader clinical use.
• The approved label and safety information, rather than a news summary, govern clinical use.

ObligationWhy confirmatory evidence is decisive

Accelerated approval allows earlier access when an endpoint is considered reasonably likely to predict clinical benefit. The tradeoff is a binding evidence obligation after approval. The sponsor must complete trial work that verifies benefit, and the FDA may reconsider the indication if the evidence does not confirm it.

The next facts to watch are the confirmatory trial's comparator, endpoints, enrollment progress, completion date and public results. Those details will determine whether the initial response signal becomes robust evidence of clinical benefit.